4.5 Review

?-Secretase inhibitors and modulators for Alzheimer's disease

期刊

JOURNAL OF NEUROCHEMISTRY
卷 120, 期 -, 页码 89-98

出版社

WILEY
DOI: 10.1111/j.1471-4159.2011.07501.x

关键词

active site; allosteric sites; amyloid; chemical probes; docking site; protease

资金

  1. NIH [NS41355, AG15379]
  2. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041355] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER

向作者/读者索取更多资源

-Secretase is a membrane embedded aspartyl protease complex with presenilin as the catalytic component. Along with beta-secretase, this enzyme produces the amyloid beta-protein of Alzheimers disease (AD) from the amyloid beta-protein precursor. Because of its key role in the pathogenesis of AD, ?-secretase has been a prime target for drug discovery, and many inhibitors of this protease have been developed. The therapeutic potential of these inhibitors is virtually negated by the fact that beta-secretase is an essential part of the Notch signaling pathway, rendering the compounds unacceptably toxic upon chronic exposure. However, these compounds have served as useful chemical tools for biological investigations. In contrast, beta-secretase modulators continue to be of keen interest as possible AD therapeutics. These modulators either shift amyloid beta-protein production to shorter, less pathogenic peptides or inhibit the proteolysis of amyloid beta-protein precursor selectively compared to that of Notch. The various chemical types of inhibitors and modulators will be discussed, along with their use as probes for basic biology and their potential as AD therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据